Myths vs facts: ApoB and Blutzucker

The question of myths vs. facts regarding ApoB and blood sugar is important because both biomarkers are closely linked to cardiometabolic risk. A common myth is that ApoB is just an alternative to LDL cholesterol. In fact, ApoB measures the number of all atherogenic particles (LDL, VLDL, IDL) and is a more precise predictor of cardiovascular disease than LDL-C alone. Another myth is that blood sugar only matters for diabetics. The fact is that elevated fasting glucose or HbA1c in the non-diabetic range is associated with higher ApoB and insulin resistance, increasing cardiovascular risk. Evidence-based medicine shows that ApoB and blood glucose should be considered together, especially in metabolic syndrome. However, many direct-to-consumer tests oversimplify these relationships, suggesting that single genes (e.g., APOA2, FTO) can provide personalized dietary advice. The actual effect sizes of such variants are small and are overridden by lifestyle factors. Conclusion: ApoB and fasting glucose are validated, clinically relevant markers. Their interpretation should rely on established cutoffs and medical advice, not on DNA tests with marketing claims.